X
After epilepsy setback, Zogenix buys Modis and rare disease drug for $400m
https://pharmaphorum.com/news/after-epilepsy-setback-zogenix-buys-modis-and-rare-disease-drug-for-400m/
Zogenix
Zogenix gains Breakthrough status, but GW Pharma still ahead in Dravet syndrome
The FDA has granted Zogenix a Breakthrough Therapy Designation for its pipeline product, ZX008 for the treatment of seizures associated with Dravet syndrome.